| 前收市價 | 17.94 |
| 開市 | 17.93 |
| 買盤 | 17.94 x 100 |
| 賣出價 | 17.98 x 100 |
| 今日波幅 | 17.90 - 18.00 |
| 52 週波幅 | 4.18 - 18.31 |
| 成交量 | |
| 平均成交量 | 608,501 |
| 市值 | 2.716B |
| Beta 值 (5 年，每月) | 0.60 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.49 |
| 業績公佈日 | 2024年8月07日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 15.55 |
ZacksNovartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
- Zacks
Novartis (NVS) to Undertake Job Cuts in Development Department
Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.
- Reuters
UPDATE 3-Novartis begins tender offer for cancer-focused MorphoSys
Novartis said on Thursday it has launched a tender offer to acquire MorphoSys , a German developer of cancer treatments, for an aggregate 2.7 billion euros ($2.9 billion). Reuters reported in February that Swiss drugmaker Novartis would buy MorphoSys, which had an equity market value of around 1.6 billion euros before the offer was announced. The Swiss drugmaker said its cash offer price of 68 euros per MorphoSys share corresponds to a premium of 142% on the volume-weighted average price during the last three months, as of the unaffected closing price on Jan. 25.
